Activation of alpha1 and alpha2 noradrenergic receptors exert opposing effects on excitability of main olfactory bulb granule cells.
The mammalian main olfactory bulb (MOB) receives a dense noradrenergic innervation from the pontine nucleus locus coeruleus that is important for neonatal odor preference learning and odor processing in mature animals. Modulation of GABAergic granule cells (GCs) is thought to play a key role in the net functional impact of norepinephrine (NE) release in the MOB, yet there are few direct studies of the influence of NE on these cells. In the present study we investigated noradrenergic modulation of GC excitability using electrophysiological approaches in rat MOB slices. A moderate concentration of NE (10 microM) and the alpha1 receptor agonist phenylephrine (10 microM) depolarized and increased spontaneous or current injection-evoked spiking in GCs. By contrast, low NE concentrations (0.1-1.0 microM) or the alpha2 receptor agonist clonidine (Clon, 10 microM) hyperpolarized and decreased the discharge of GCs. The effects of NE (10 microM) were blocked by antagonism of alpha1 and alpha2 receptors. Inhibitory effects of low NE concentrations were blocked or converted to excitatory responses by alpha2 receptor blockade, whereas excitatory effects of the moderate NE concentration were converted to inhibitory responses after alpha1 receptor blockade. NE (10 microM) and phenylephrine elicited inward currents that reversed near the potassium equilibrium potential. The effects of NE and phenylephrine were associated with increased membrane input resistance. Clonidine elicited an outward current associated with decreased membrane input resistance that reversed near the potassium equilibrium potential. These results indicate that alpha1 and alpha2 receptor activation exert opposing effects on GC excitability. Low concentrations of NE acting via alpha2 receptors suppress GC excitability, while higher concentrations of NE acting at alpha1 receptors increase GC excitability. These findings are consistent with recent findings that alpha1 and alpha2 receptor activation increase and decrease, respectively, GABAergic inhibition of mitral cells. The differential affinities of alpha1 and alpha2 noradrenergic receptor subtypes may allow for differential modulation of GABA release and olfactory processing as a function of the level of NE release, which in turn, is regulated by behavioral state.
Nai
Q
Q
Department of Anatomy and Neurobiology, University of Tennessee Health Science Center, Memphis, TN 38163, USA. qnai@uthsc.edu
Dong
H W
HW
Linster
C
C
Ennis
M
M
D058646:Adrenergic alpha-1 Receptor Agonists; D058668:Adrenergic alpha-1 Receptor Antagonists; D058647:Adrenergic alpha-2 Receptor Agonists; D058669:Adrenergic alpha-2 Receptor Antagonists; D000818:Animals; D003000:Clonidine / Q000494:pharmacology; D005071:Evoked Potentials / Q000187:drug effects; D005260:Female; D066298:In Vitro Techniques; D008297:Male; D008564:Membrane Potentials / Q000187:drug effects; D009474:Neurons / Q000187:drug effects* / Q000502:physiology; D009638:Norepinephrine / Q000494:pharmacology; D009830:Olfactory Bulb / Q000166:cytology / Q000187:drug effects* / Q000502:physiology; D018408:Patch-Clamp Techniques; D010656:Phenylephrine / Q000494:pharmacology; D051381:Rats; D017207:Rats, Sprague-Dawley
D058646:Adrenergic alpha-1 Receptor Agonists; D058668:Adrenergic alpha-1 Receptor Antagonists; D058647:Adrenergic alpha-2 Receptor Agonists; D058669:Adrenergic alpha-2 Receptor Antagonists; D010656:Phenylephrine; D003000:Clonidine; D009638:Norepinephrine
Proc Natl Acad Sci U S A. 1995 Apr 11;92(8):3371-5
7724568
J Neurophysiol. 2007 Jan;97(1):858-70
17093122
J Neurosci. 2001 Oct 1;21(19):7491-505
11567039
Eur J Neurosci. 1995 Dec 1;7(12):2370-8
8845941
Adv Pharmacol. 1998;42:749-54
9328007
Neuroscience. 1993 Nov;57(1):143-51
8278048
J Physiol. 1994 Aug 1;478 Pt 3:437-47
7525947
J Neurosci Methods. 2005 Jul 15;146(1):69-75
15935222
J Comp Neurol. 1989 Jul 15;285(3):339-49
2547851
J Neurosci. 1992 Oct;12(10):3992-8
1403095
J Neurosci. 2004 Dec 1;24(48):10773-85
15574728
Learn Mem. 2006 Jan-Feb;13(1):8-13
16452650
Pharmacol Ther. 2007 Mar;113(3):523-36
17303246
Neuroscience. 1997 Jan;76(1):261-72
8971776
J Neurosci. 1994 Jul;14(7):4252-68
8027777
J Neurosci. 1992 Oct;12(10):3985-91
1328562
Learn Mem. 2007 Dec 17;14(12):847-54
18086828
Can J Physiol Pharmacol. 1992;70 Suppl:S92-7
1338301
Learn Mem. 2007 Aug 03;14(8):539-47
17686948
J Neurosci. 1994 Jul;14(7):4467-80
8027789
J Neurophysiol. 2009 Aug;102(2):1103-14
19474170
Brain Res. 1987 Mar 10;405(2):348-52
3567613
Neuron. 2000 Feb;25(2):399-410
10719894
J Physiol. 1984 Apr;349:43-55
6145790
J Physiol. 1995 May 15;485 ( Pt 1):113-20
7658366
Neuroscience. 1997 Jan;76(1):241-60
8971775
J Chem Neuroanat. 1997 Jul;13(2):115-39
9285356
Brain Res. 1985 Mar 11;329(1-2):294-9
3978450
Brain Res Brain Res Rev. 2003 Apr;42(1):33-84
12668290
J Physiol. 1987 Dec;393:213-31
2895810
J Neurosci. 2006 Mar 22;26(12):3292-8
16554479
Eur J Pharmacol. 1979 Nov 16;59(3-4):317-9
230976
J Neurophysiol. 2001 Nov;86(5):2173-82
11698509
J Neurosci. 1993 May;13(5):2199-216
8386756
Eur J Neurosci. 2008 Mar;27(5):1210-9
18364038
J Comp Neurol. 1996 Aug 12;372(1):111-34
8841924
Behav Neurosci. 2008 Aug;122(4):816-26
18729635
Synapse. 2000 Sep 15;37(4):273-82
10891864
Behav Brain Res. 1997 Mar;84(1-2):117-27
9079778
Nat Rev Neurosci. 2001 Mar;2(3):175-84
11256078
J Comp Neurol. 1997 Sep 29;386(3):358-78
9303423
Nature. 1982 May 20;297(5863):227-9
7078637
Brain Res. 1986 Oct 15;385(1):122-35
3768710
J Neurosci. 1998 Sep 1;18(17):6963-76
9712665
J Neurosci. 2006 Sep 27;26(39):9860-72
17005850
J Neurophysiol. 2009 May;101(5):2472-84
19279145
Eur J Neurosci. 2001 Mar;13(6):1093-100
11285006
Proc Natl Acad Sci U S A. 1980 Mar;77(3):1696-700
6246501
Behav Neurosci. 2000 Oct;114(5):957-62
11085610
J Physiol. 1996 Jan 15;490 ( Pt 2):373-81
8821136
J Neurosci. 1996 Jan 15;16(2):572-85
8551341
J Comp Neurol. 1985 Jan 8;231(2):190-208
2981906
J Neurosci. 2007 May 23;27(21):5654-63
17522310
J Neurosci. 1993 Sep;13(9):3878-83
8103553